| Abstrakt: |
A recent study conducted by researchers at Hainan University in Haikou, China, has identified a potential treatment for liver fibrosis, a common feature of chronic liver diseases. The researchers focused on phosphodiesterase 1 (PDE1), a subfamily of enzymes that regulate the concentration of cAMP and cGMP, and found that compound AG-205/1186117, a dihydropyrimidine derivative, exhibited promising results as a PDE1 inhibitor. Lead compound 13h demonstrated high selectivity against other PDEs and showed significant anti-liver fibrotic effects in animal models. This research suggests that PDE1 could be a potential target for liver fibrosis treatment. [Extracted from the article] |
